Germany's CureVac ditches first-generation COVID jab

Germany's CureVac said Tuesday it is no longer seeking European regulatory approval for its coronavirus vaccine, and will focus instead on a more promising second-generation jab.


Roche sees pharma market recovering from COVID

Swiss pharmaceutical firm Roche said Thursday that drug sales have begun to recover from a COVID-induced slump as it confirmed forecasts for a modest increase in sales for the year as a whole.

Diseases, Conditions, Syndromes

Interim trial data shows low effectiveness for CureVac shot

German vaccine maker CureVac said Wednesday that interim data from late-stage testing of its coronavirus shot show a comparatively low effectiveness in protecting people against COVID-19.


Novavax starts COVID-19 vaccine trials on children

US biotech firm Novavax said Monday it had started clinical trials of its proposed COVID-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17.

page 1 from 6